Originally published on Fri August 24, 2012 1:19 pm
An experimental drug that aimed to slow the development of plaques and help clear them from the brains of Alzheimer's patients failed in two late-stage studies conducted by Eli Lilly & Co., the company said today.
Counselors have long cautioned about the downsides of genetic testing for Alzheimer's disease.
For one thing, the current genetic tests for late-onset Alzheimer's — the type that develops after age 60 and is responsible for more than 90 percent of cases — only indicate a probability of getting the disease. It's not definitive. And consumers' ability to buy life insurance or long-term care coverage could be jeopardized by the results.
Originally published on Thu April 19, 2012 10:39 am
Activity cuts the risk of Alzheimer's disease and slows cognitive decline, even in the very old, according to a new study.
There's been plenty of evidence for the "use it or lose it" theory of brain capacity. But this study is one of the first to show that activity of all sorts benefits people over age 80, even if they're not "exercising."